Comparative Pharmacology
Head-to-head clinical analysis: DIONOSIL AQUEOUS versus IOHEXOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIONOSIL AQUEOUS versus IOHEXOL.
DIONOSIL AQUEOUS vs IOHEXOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DIONOSIL AQUEOUS contains propyliodone, a radiocontrast agent that absorbs X-rays, providing visualization of bronchial structures. It acts by coating the bronchial mucosa and filling the airways, allowing radiographic imaging.
Non-ionic, water-soluble, iodinated contrast agent that increases the radiopacity of vascular structures and body cavities, allowing visualization during radiographic procedures. It does not bind to serum proteins and is rapidly distributed in extracellular fluid.
Intra-articular injection: 2-3 mL of 1% solution (20-30 mg) per joint; maximum 4 joints per session. Intravenous: 2-4 mL of 20% solution (400-800 mg) diluted in 20 mL water, administered slowly over 5-10 minutes, for peripheral angiography.
Intravenous: 300-370 mg iodine/kg (0.3-0.37 mL/kg of 300 mg I/mL solution) for contrast imaging; typical range 15-150 mL per procedure depending on examination. Intra-arterial: Doses vary by procedure, typically 1-10 mL total. Do not exceed 3 mL/kg total dose.
None Documented
None Documented
Clinical Note
moderateIohexol + Metformin
"The risk or severity of adverse effects can be increased when Iohexol is combined with Metformin."
Terminal elimination half-life is 2-4 hours in patients with normal renal function; prolonged in renal impairment.
Terminal elimination half-life approximately 2-3 hours in patients with normal renal function. In patients with severe renal impairment (CrCl <30 mL/min), half-life may be prolonged up to 30-60 hours, necessitating dose adjustment or avoidance.
Renal excretion of unchanged drug accounts for >95% of elimination; <5% is eliminated via biliary/fecal routes.
Primarily renal via glomerular filtration; 90-100% of administered dose excreted unchanged in urine within 24 hours. Less than 2% excreted in feces. Biliary excretion negligible (<1%).
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent